Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNF | P01375 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 2/20 | 0.38 |
| ▸ | CA9 | Q16790 | 2/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | CA4 | P22748 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | CA12 | O43570 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2280493 | 1.00 | TNF (0.47) | TNFALDH1A1MEN1KMT2AMAPK1 | |
| SCHEMBL24813373 | 0.86 | TNF (0.49) | TNFALDH1A1MEN1KMT2AMAPK1 | |
| SCHEMBL29144184 | 0.86 | TNF (0.49) | TNFALDH1A1MEN1KMT2AMAPK1 | |
| SCHEMBL30049141 | 0.86 | TNF (0.49) | TNFALDH1A1MEN1KMT2AMAPK1 | |
| SCHEMBL5027411 | 0.85 | TNF (0.45) | TNFALDH1A1MEN1KMT2AMAPK1 | |
| SCHEMBL2282582 | 0.84 | MEN1 (0.54) | TNFALDH1A1MEN1KMT2AMAPK1 | |
| SCHEMBL2168623 | 0.84 | MEN1 (0.54) | TNFALDH1A1MEN1KMT2AMAPK1 | |
| SCHEMBL29790477 | 0.84 | MEN1 (0.54) | TNFALDH1A1MEN1KMT2AMAPK1 | |
| SCHEMBL2282489 | 0.84 | MEN1 (0.54) | TNFALDH1A1MEN1KMT2AMAPK1 | |
| SCHEMBL2288486 | 0.83 | ATM (0.46) | TNFALDH1A1MEN1KMT2AMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10266514-B2 | Processes for the preparation of 4-amino-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione compounds | CELGENE CORPORATION (US) | 2019-04-23 | — | — | US | disclosed |
| US-20180044318-A1 | PROCESSES FOR THE PREPARATION OF 4-AMINO-2-(2,6-DIOXOPIPERIDIN-3-YL)ISOINDOLINE-1,3-DIONE COMPOUNDS | CELGENE CORP (US) | 2018-02-15 | — | — | US | disclosed |
| US-9822093-B2 | Processes for the preparation of 4-amino-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione compounds | CELGENE CORPORATION (US) | 2017-11-21 | — | — | US | disclosed |
| WO-2017134476-A1 | METHOD FOR THE PRODUCTION OF POMALIDOMIDE | EGIS GYÓGYSZERGYÁR ZRT. (HU) | 2017-08-10 | — | — | WO | disclosed |
| US-20160297791-A1 | PROCESSES FOR THE PREPARATION OF 4-AMINO-2-(2,6-DIOXOPIPERIDIN-3-YL)ISOINDOLINE-1,3-DIONE COMPOUNDS | CELGENE CORP (US) | 2016-10-13 | — | — | US | disclosed |
| US-9394274-B2 | Processes for the preparation of 4-amino-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione compounds | CELGENE CORPORATION (US) | 2016-07-19 | — | — | US | disclosed |
| US-20140256950-A1 | PROCESSES FOR THE PREPARATION OF 4-AMINO-2-(2,6-DIOXOPIPERIDIN-3-YL)ISOINDOLINE-1,3-DIONE COMPOUNDS | CELGENE CORPORATION (US) | 2014-09-11 | — | — | US | disclosed |
| US-8785644-B2 | Processes for the preparation of 4-amino-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione compounds | CELGENE CORPORATION (US) | 2014-07-22 | — | — | US | disclosed |
| EP-2380887-B1 | Processes for the preparation of 4-amino-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione compounds | CELGENE CORP (US) | 2013-08-07 | — | — | EP | disclosed |
| EP-1907373-B1 | PROCESSES FOR THE PREPARATION OF 4-AMINO-2-(2,6-DIOXOPIPERIDIN-3-YL)ISOINDOLINE-1,3-DIONE COMPOUNDS | CELGENE CORP (US) | 2013-01-09 | — | — | EP | disclosed |
| EP-2380887-A1 | Processes for the preparation of 4-amino-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione compounds | Celgene Corporation (US) | 2011-10-26 | — | — | EP | disclosed |
| US-20110224440-A1 | PROCESSES FOR THE PREPARATION OF 4-AMINO-2-(2,6-DIOXOPIPERIDIN-3-YL)ISOINDOLINE-1,3-DIONE COMPOUNDS | CELGENE CORPORATION | 2011-09-15 | — | — | US | disclosed |
| US-7994327-B2 | Processes for the preparation of 4-amino-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione compounds | CELGENE CORPORATION (US) | 2011-08-09 | — | — | US | disclosed |
| EP-1907373-A1 | PROCESSES FOR THE PREPARATION OF 4-AMINO-2-(2,6-DIOXOPIPERIDIN-3-YL)ISOINDOLINE-1,3-DIONE COMPOUNDS | CELGENE CORPORATION (US) | 2008-04-09 | — | — | EP | disclosed |
| WO-2007005972-A1 | PROCESSES FOR THE PREPARATION OF 4-AMINO-2-(2,6-DIOXOPIPERIDIN-3-YL)ISOINDOLINE-1,3-DIONE COMPOUNDS | CELGENE CORPORATION (US) | 2007-01-11 | — | — | WO | disclosed |
| US-20070004920-A1 | Processes for the preparation of 4-amino-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione compounds | CELGENE CORPORATION AN ORGNIZATION OF THE STATE NEW JERSEY (US) | 2007-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110224440-A1 | PROCESSES FOR THE PREPARATION OF 4-AMINO-2-(2,6-DIOXOPIPERIDIN-3-YL)ISOINDOLINE-1,3-DIONE COMPOUNDS | TNF, TRAF2, IL1A | TNF 1/4885ALDH1A1 245/4885MEN1 4003/4885 |
| US-20160297791-A1 | PROCESSES FOR THE PREPARATION OF 4-AMINO-2-(2,6-DIOXOPIPERIDIN-3-YL)ISOINDOLINE-1,3-DIONE COMPOUNDS | TNF, TRAF2, IL1A | TNF 1/4885ALDH1A1 245/4885MEN1 4003/4885 |
| US-10266514-B2 | Processes for the preparation of 4-amino-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione compounds | TNF, TRAF2, IL1A | TNF 1/4885ALDH1A1 245/4885MEN1 4003/4885 |
| US-20070004920-A1 | Processes for the preparation of 4-amino-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione compounds | TNF, DHPS, IL1A | TNF 1/4885ALDH1A1 77/4885MEN1 3805/4885 |
| US-20140256950-A1 | PROCESSES FOR THE PREPARATION OF 4-AMINO-2-(2,6-DIOXOPIPERIDIN-3-YL)ISOINDOLINE-1,3-DIONE COMPOUNDS | TNF, TRAF2, IL1A | TNF 1/4885ALDH1A1 245/4885MEN1 4003/4885 |
| US-20180044318-A1 | PROCESSES FOR THE PREPARATION OF 4-AMINO-2-(2,6-DIOXOPIPERIDIN-3-YL)ISOINDOLINE-1,3-DIONE COMPOUNDS | TNF, TRAF2, IL1A | TNF 1/4885ALDH1A1 245/4885MEN1 4003/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.